By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Merrimack Pharmaceuticals Inc. 

101 Binney Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-441-1000 Fax: 617-491-1386


SEARCH JOBS



Segment
Start Up

Collaborations

Dyax Corp.  Antibody phage display





Company News
Merrimack Pharmaceuticals Inc. (MACK) Presents Additional Phase 2 Biomarker Data Further Strengthening The Finding That MM-121 Increases Progression Free Survival In Patients With Biomarker Positive Metastatic Breast Cancer 9/30/2014 7:40:45 AM
Baxter International, Inc. (BAX)'s Deal With Merrimack Pharmaceuticals Inc. (MACK) All Upside: Analyst 9/26/2014 12:04:50 PM
Baxter International, Inc. (BAX) Inks A $970 Million Pact For Merrimack Pharmaceuticals Inc. (MACK)'s Lead Cancer Drug MM-398 9/24/2014 6:02:00 AM
Merrimack Pharmaceuticals Inc. (MACK)To Present Clinical And Biomarker Data On Novel Antibody Therapeutics At The ESMO 2014 Congress 9/19/2014 7:18:06 AM
Merrimack Pharmaceuticals Inc. (MACK) Reports Second Quarter 2014 Financial Results 8/11/2014 7:41:11 AM
Merrimack Pharmaceuticals Inc. (MACK) Announces Initiation Of HERMIONE, A Randomized Trial Of MM-302 In Patients With Advanced HER2-Positive Breast Cancer To Support Application For Accelerated Approval 8/11/2014 7:33:02 AM
Merrimack Pharmaceuticals Inc. (MACK) Announces Timing Of Second Quarter 2014 Investor Conference Call 8/4/2014 3:38:56 PM
Merrimack Pharmaceuticals Inc. (MACK) Presents Data From Phase 3 NAPOLI-1 Study At The ESMO 16th World Congress On Gastrointestinal Cancer 6/26/2014 7:39:47 AM
Sanofi (France) (SAN.PA) Throws Cancer Drug Back To Merrimack Pharmaceuticals Inc. (MACK) 6/20/2014 6:57:26 AM
Merrimack Pharmaceuticals Inc. (MACK) Announces Oral Presentation Of Additional Data Results In Phase 3 NAPOLI-1 Study At The ESMO 16th World Congress On Gastrointestinal Cancer 6/17/2014 8:50:14 AM
12345678910...
//-->